Addition of sodium glucose cotransporter 2 (SGLT2) inhibitor to glucagon-like peptide-1 (GLP-1) receptor agonist therapy in obese people with Type 2 diabetes and suboptimal glycaemic control

被引：0
|
作者：
Curtis, L. R. [1 ]
Walker, J. I. [1 ]
Knott, J. [1 ]
Partridge, H. L. [1 ]
机构：
[1] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Diabet & Endocrine Ctr, Bournemouth, Dorset, England
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P529
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [21] Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
    Busch, Robert S.
    Kane, Michael P.
    POSTGRADUATE MEDICINE, 2017, 129 (07) : 686 - 697
  • [22] A synergistic duo : Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor therapy in the management of Type 2 Diabetes
    O'Connor, T.
    Griffin, S.
    Moore, K.
    Woods, C.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 : S244 - S244
  • [23] GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
    Neves, Joao Sergio
    Borges-Canha, Marta
    Vasques-Novoa, Francisco
    Green, Jennifer B.
    Leiter, Lawrence A.
    Granger, Christopher B.
    Carvalho, Davide
    Leite-Moreira, Adelino
    Hernandez, Adrian F.
    Del Prato, Stefano
    McMurray, John J. V.
    Md, Joao Pedro Ferreira
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 517 - 525
  • [24] Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
    Kim, Hwi Seung
    Yoon, Taekwan
    Jung, Chang Hee
    Park, Joong-Yeol
    Lee, Woo Je
    DIABETES & METABOLISM JOURNAL, 2022, 46 (04) : 658 - 662
  • [25] Gender and Racial Disparities in Patients Using Sodium-Glucose Cotransporter-2 ( SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Analogues in a Real-World Scenario
    Tuli, Aakash
    Varghese, Jobin
    Smith, Damien
    Garcia-Garcia, Hector
    CIRCULATION, 2022, 146
  • [26] The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
    Shami, Dalia
    Sousou, John M.
    Batarseh, Einas
    Alazrai, Laith
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [27] Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
    Williams, David M.
    Atkinson, Michael
    Evans, Marc
    STROKE, 2023, 54 (05) : 1441 - 1451
  • [28] Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study
    Wei, Yuanbo
    Ma, Huihui
    Wei, Tianshuai
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2024, 20 (04) : 672 - 681
  • [29] Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
    Hiramatsu, Takeyuki
    Ito, Hiroki
    Okumura, Shota
    Asano, Yuko
    Iguchi, Daiki
    Furuta, Shinji
    DIABETES & VASCULAR DISEASE RESEARCH, 2020, 17 (06)
  • [30] Association of Copayment Level and Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Adherence in Diabetes and Heart Failure
    Essien, Utibe R.
    Singh, Balvindar
    Swabe, Gretchen
    Johnson, Amber E.
    Eberly, Lauren
    Wadhera, Rishi
    Breathett, Khadijah
    Vaduganathan, Muthiah
    Magnani, Jared W.
    CIRCULATION, 2023, 147
12345